Questions with somewhere to go
Research at NEUVIOR begins with a question whose answer could change a decision or open a route to development. Our programmes span medicines technology, therapeutic research, and industrial pharmaceutical innovation.
How does medicines evidence become useful action
PHARMORIS research examines the path from evidence preparation to professional review, implementation, and realised value. Our questions concern source reliability, review burden, local adoption, and the economics of introducing a change.
Which cells help glioblastoma return
Our biomedical programme asks which malignant survivors contribute to regrowth after treatment. It examines a possible GPX4-related vulnerability alongside the need for a selective, development-ready intervention rationale.
What should a pharmaceutical material be able to do
ZYLON connects bio-derived materials and resource recovery with the requirements of a real manufacturing application. A candidate material needs a clear use, reproducible performance, and a credible account of its wider costs and impacts.
When does predictive control earn its place
PHARMORIS-ECO examines fixed pharmaceutical chilling and freezing. It compares predictive approaches with credible existing controls, asking where additional complexity can improve energy performance whilst maintaining required conditions.
Read the work as it develops
Our research pages distinguish the question being investigated, the evidence that informs it, and the next result needed to advance it. Publications and methods will connect an output to the programme and decision it informs.
Continue the programme
- Glioblastoma Recurrence Programme
Read about NEUVIOR’s glioblastoma research into treatment-surviving malignant cell states, regrowth, therapeutic selectivity, and GPX4-related questions.
- Understanding glioblastoma
Read accessible explanations of glioblastoma, diagnosis, treatment, recurrence, cell states, and the research questions behind NEUVIOR’s programme.
- Glioblastoma programme investment
Read about the development questions and evidence milestones behind NEUVIOR’s glioblastoma programme, from survivor biology to a potential intervention.
- Research collaboration
Read about research collaboration with NEUVIOR across medicines implementation, glioblastoma biology, pharmaceutical materials, and energy research.
- Publications and methods
Read about NEUVIOR’s research questions and the place of publications, methods, and study outputs across medicines, biology, and industrial research.